On Friday's news that Biohaven (NYSE: BHVN) withdrew its application for a top investigational drug from an important ...

RBC Capital after notes released by the European Medicines Agency’s CHMP indicated that Biohaven (BHVN) had withdrawn the application for ...

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as ...

EDT Biohaven (BHVN) down 12% to $20.60 after pulling European applicationStay Ahead of the Market: Discover outperforming stocks and ...

Investing.com -- Biohaven Pharma (NYSE: BHVN) shares fell sharply by as much as 21% as the company withdrew its marketing authorization application for Dazluma in Europe, intended to treat ...

“While there’s still a lot to learn, these findings show that regular intensity exercise, even at low intensity, could go a ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

The leading Migraine Companies such as ​ Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity ...

M42, the Abu Dhabi-based tech-enabled global health company specializing in artificial intelligence (AI), advanced technology ...

Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...